fda2WASHINGTON, D.C. (5/15/13) - The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product’s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency’s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.

“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.”

In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.

Xofigo’s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo’s ability to extend overall survival.

The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).

Xofigo is marketed by Wayne, N.J.-based Bayer Pharmaceuticals. Xtandi is co-marketed by Astellas Pharma U.S., Inc. of Northbrook, Ill., and Medivation, Inc. of San Francisco, Calif.
 
SurfKY News
Information provided by the United States Food and Drug Administration

e-max.it: your social media marketing partner

LIKE SurfKY on Facebook - Click here to LIKE us now.

© Copyright 2015 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story on social media.

In Other News...

Martin Scholar Spotlight - Amy Douglas

MADISONVILLE, Ky. (7/30/15) — The Muhlenberg County Campus of Madisonville Community College is proud to announce the… Read More

Muhlenberg County Head Start Preschool Program Accepting Applications

CENTRAL CITY, Ky. (7/29/15) — The Muhlenberg County Head Start Preschool program is now accepting applications for… Read More

Most Read This Week

July 27, 2015 5525

Death of Central City Man in Dawson Springs Under…

by SurfKY News
July 27, 2015 3708

School System Announces Free Lunch/Breakfast at…

by SurfKY News
July 29, 2015 2331

Miss Hopkins County Fair 2015 Chosen

by Tammy Holloway, SurfKY News
July 28, 2015 2313

Hanson, Owensboro, Bowling Green Youths Win at…

by Tammy Holloway, SurfKY News
July 27, 2015 2223

Family Needs Help in Paying 18-Year-Old's Funeral…

by SurfKY News

Most Read This Month

July 02, 2015 19685

Emergency Response Team on Scene of Standoff on…

by Doreen Dennis, SurfKY News
July 17, 2015 15922

Muhlenberg Most Wanted - Top 10

by SurfKY News

Stories Trending Now

July 29, 2015 2331

Miss Hopkins County Fair 2015 Chosen

by Tammy Holloway, SurfKY News
July 29, 2015 2044

Crime Stoppers Top Most Wanted - July 29, 2015

by SurfKY News
July 28, 2015 2040

Heavy Rains, Two Wrecks Impede WKP Travel

by Doreen Dennis, SurfKY News
July 30, 2015 1897

Webster Man Leads Police on Chase through Parts…

by SurfKY News
July 29, 2015 1474

PPD Warns Public: Beware of Facebook Scam

by SurfKY News
July 29, 2015 1316

24th Annual Miss Teen Hopkins County Fair Pageant…

by Tammy Holloway, SurfKY News
July 29, 2015 1236

Madisonville Police Arrest Reports Released -…

by SurfKY News
July 29, 2015 1071

Local Teen Cited on Charges for Alleged…

by SurfKY News
July 29, 2015 985

Hanson City Council Discusses Boundaries, Zoning

by Tammy Holloway, SurfKY News
July 29, 2015 760

Yeti Spotted at Hanson Pharmacy

by SurfKY News